Bronchipret

Quick links to important sections

Bronchipret

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bronchipret

Bronchipret is a well-established, multi-component phytotherapeutic (herbal) medicine from the German manufacturer Bionorica SE. It is primarily used to relieve symptoms associated with acute inflammation of the airways, especially coughs that produce excessive or thick mucus. The product is generally available over-the-counter (OTC) and utilizes a fixed-dose combination of plant extracts to provide a comprehensive effect, aiming to loosen mucus (expectorant action) and soothe the inflamed bronchial lining.

Property Description
Active Ingredients Thyme herb and Ivy leaves (or Primrose root) extracts
Form Syrup, Drops, or Film-Coated Tablets
Pharmacological Class Herbal medicine/Phytotherapeutic agent
Manufacturer Bionorica SE (Germany)
Common Use Improving symptoms of acute bronchitis with productive cough

Its key active components are typically Thyme herb extract combined with either Ivy leaf extract (in formulations like Syrup TE and Drops) or Primrose root extract (in the TP Tablet formulation). Ivy leaf extract, a component in Bronchipret, is recognized as a traditional herbal medicine used as an expectorant for productive coughs. This confirms that the plant ingredients have a long history of use for helping to expel phlegm from the respiratory passages.

The combined formulation is designed to offer multiple therapeutic actions. The efficacy of the combination of thyme and ivy extracts in relieving cough symptoms is supported by pharmacological studies. The overall goal is to relieve patient discomfort by helping to clear the bronchi and reduce the intensity of cough fits.

Regulatory References

  1. EMA herbal monograph on Thymi herba (Thyme)

What side effects are possible with Bronchipret?

Possible Side Effects and Safety Information

Adverse Reactions

The safety profile for Bronchipret, based on regulatory documentation, is characterized by two main categories of potential adverse reactions: Gastrointestinal Disorders and Immune System Disorders (Hypersensitivity).

Classification System/Organ Class Adverse Reaction
Uncommon (Up to 1 in 100) Gastrointestinal Cramps, nausea, vomiting, or diarrhea.
Very Rare (Less than 1 in 10,000) Immune System, Skin Hypersensitivity (allergic) reactions.

Serious adverse reactions are primarily the hypersensitivity reactions which, in very rare cases, may present as shortness of breath, urticaria (hives), or swelling of the face, mouth, and/or throat. Use must be stopped immediately at the first sign of an allergic reaction.

Safety Restrictions and Monitoring

Safety Restrictions for Use:

  • Hypersensitivity: The product is contraindicated if there is a known allergy to the active substances (Thyme, Primrose, or Ivy extracts, depending on the formulation), other plants of the Lamiaceae family, or any other ingredients.
  • Pregnancy and Breast-feeding: Use is not recommended due to a lack of sufficient data on safety in these populations.
  • Pediatric Use: Specific restrictions apply depending on the formulation (e.g., drops generally not for children under 6 years; tablets not for children under 12 years).

Special Caution: Individuals with a history of gastritis or stomach ulcers should use the product with caution.

Overdose may lead to gastrointestinal discomfort, vomiting, and possibly diarrhea. Regulatory advice mandates immediate medical consultation in case of a suspected overdose.

Monitoring Notes: A doctor should be consulted immediately if symptoms last longer than one week, or if shortness of breath, fever, or purulent or bloody expectoration occurs.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Bronchipret

Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations Overdose may lead to gastrointestinal complaints, including stomach discomfort, vomiting, and possibly diarrhoea.
Physiological systems affected (as stated in label) Primarily the Gastrointestinal System.
Dose-related or exposure-related factors (if applicable) Manifestations occur upon taking more than the instructed amount. Specific toxic dose thresholds are not detailed in the regulatory overdose section.
Population-specific overdose notes (if applicable) No specific overdose considerations for distinct populations (e.g., pediatric, elderly, organ impairment) are documented in the official overdose sections reviewed.
Emergency-response statements (as written in official documents) A doctor must be notified in the event of an overdose. The physician "can decide whether any other action is necessary."
When immediate medical help is required (label-derived phrasing only) Immediate medical consultation is mandated if shortness of breath, fever, or purulent or bloody sputum/expectoration occurs.

Overdose Classifications (high-level)

Element Official Regulatory Statement
Severity classification (as defined in official documents) Not explicitly classified; documented effects indicate non-severe acute toxicity (gastrointestinal upset). No life-threatening outcomes are directly attributed to overdose.
Regulatory basis (EMA / FDA / etc.) Based on the Summary of Product Characteristics (SmPC) / Patient Information Leaflet derived from national European health agencies.
Overdose-context constraints (as defined in official documents) Management is determined by the healthcare provider and is typically symptomatic and supportive. No specific antidote is mentioned in the official labeling.

Resulting Overdose Structure

Official overdose statements:

  • Ingesting more than the recommended amount may result in the manifestation of stomach discomfort, vomiting, and diarrhoea.
  • In the event of an overdose, a doctor must be notified so the professional can determine the required supportive measures or further action.
  • Urgent medical attention is specifically required if the patient experiences fever, shortness of breath, or expectorates purulent or bloody matter.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by describing a limited range of expected clinical manifestations, primarily transient gastrointestinal distress. This profile requires the user to notify a doctor for assessment and potential symptomatic management, which is consistent with the lack of a documented specific antidote. Furthermore, the regulatory labeling establishes strict, non-overdose-related triggers—specifically fever or shortness of breath—that mandate immediate medical help-seeking regardless of the amount consumed.

Therapeutic Uses of Bronchipret

What Bronchipret Treats: Main Uses and Benefits

The combined herbal extracts in Bronchipret are commonly used to provide support in managing symptoms associated with acute respiratory conditions. Its ingredients are traditionally used as an expectorant to help relieve the symptoms of bronchitis and cough. This application is relevant within clinical settings that involve acute or disruptive symptom patterns.

Symptomatic Relief and Indications

Bronchipret is generally applied across therapeutic domains involving symptomatic discomfort linked to acute inflammation of the airways, most commonly in cases of acute bronchitis. It helps address symptom clusters that may appear suddenly, providing a supportive role in managing symptoms of a productive cough, excessive or thick mucus accumulation, and general airway irritation. The application is intended to provide support that helps ease the overall symptom burden during an acute episode.

“The primary goal of use is to help patients cope more steadily with difficult manifestations by assisting with the management of congestion and cough.”

This medication is relevant for managing symptoms related to a productive cough and congested mucus, used when short-term symptomatic assistance is needed. It is also applied in scenarios where additional management of discomfort is required due to airway irritation. This contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Productive Cough The medication is relevant for addressing symptoms that involve thick secretions in the chest, offering support to ease the overall strain and burden of the cough.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documents define specific populations who are eligible to use Bronchipret and those who must be excluded, primarily based on age and known allergies.


Populations Who Must Not Use Bronchipret (Contraindications)

Use is strictly contraindicated for individuals with a known hypersensitivity or allergy to the active ingredients (thyme, ivy, or primrose root, depending on the formulation) or to other related plants (such as Aralia family, Labiatae/Lamiaceae, birch, mugwort, or celery), or to any of the product's excipients.


Age-Related Eligibility

The approved minimum age for use varies by the product formulation:

Formulation Minimum Eligible Age
Syrup (Thyme/Ivy) Children from 1 year of age. Use in children under 1 year is contraindicated.
Tablets (Thyme/Primrose) Adolescents from 12 years of age. Use in children under 12 years is not recommended due to insufficient data.

Special Patient Groups and Conditions

  • Pregnancy and Lactation: The medicine should not be used during pregnancy or breast-feeding due to insufficient clinical data to establish its safety in these physiological states.
  • Underlying Conditions: Patients with a history of gastritis or peptic ulcers should use the medicine only after consulting a healthcare professional.
  • Excipient Restrictions: Individuals with known intolerances to certain sugars (e.g., maltitol or lactose, depending on the form) must consult a doctor before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for the combination of thyme and ivy extracts in Bronchipret indicates a minimal known interaction profile with other medicinal products. To date, no known interactions with other simultaneously administered medicines have been reported or documented in authoritative sources.


Interaction Status Summary

Interaction Type Official Regulatory Statement
Known Interactions None officially known/listed
Specific Interacting Medicines None explicitly listed
Mechanistic Basis Not stated in the regulatory documents
Timing or Constraints No specific timing or procedural constraints are defined for interactions

This absence of documented interactions does not definitively rule out all possibilities. The product's composition, which includes herbal extracts, means comprehensive studies on pharmacokinetic or pharmacodynamic interactions with all other medications, including over-the-counter remedies and supplements, have not been conducted.

Patients should always inform their healthcare provider or pharmacist about all medicines, supplements, or herbal products they are currently taking or have recently taken. This procedural step helps ensure the safe co-administration of products and allows a professional to assess the overall treatment regimen for potential issues.

Mechanism of Action

Dual Modulation of Airway Smooth Muscle and Inflammatory Signaling

The mechanism of action for Bronchipret, a fixed combination of plant extracts, is delivered through a multi-target action influencing smooth muscle tone, inflammatory signaling, and secretory dynamics. The Ivy leaf components modulate the beta2-Adrenergic Receptor (beta2-AR) and Thyme components inhibit the enzyme Phosphodiesterase 4 (PDE4). This dual intervention sustains elevated intracellular levels of the signaling molecule cAMP, which promotes the spasmolytic effect and influences airflow dynamics.

Simultaneously, the components modulate pathways associated with inflammation by inhibiting the enzyme 5-Lipoxygenase (5-LO) and suppressing the transcription factor NF-kappaB. By restricting these regulators, the mechanism limits the release of pro-inflammatory Leukotrienes and cytokines, resulting in reduced bronchial tissue hyperreactivity.

Secretion Fluidity and Ciliary Transport

The elevated cAMP levels alter ion and water transport across the epithelial lining, resulting in less viscous, thinner mucus. Components also increase the ciliary beat frequency (CBF), contributing to the mobilization and expulsion of secretions from the respiratory tract.

Dosage and Administration Information

How to Use Bronchipret: Administration Guidelines

The usage of this multi-component herbal medicine is defined by administration and dosing guidelines. The route for all available forms (Syrup, Drops, and Film-Coated Tablets) is oral ingestion.


Administration Scope

Instruction Detail
Dosing Schedule Standardized as a specific single dose volume or unit repeated three times daily (t.i.d.) for all approved age groups.
Timing in Relation to Meals Film-Coated Tablets (TP) must be swallowed before meals. Liquid forms (Syrup/Drops) may be taken independent of meals, with the recommendation of consumption after meals for those with a sensitive stomach.
Preparation Requirements Liquid forms must be shaken well before use and measured using the enclosed calibrated device. Tablets must be swallowed unchewed with a sufficient quantity of liquid.
Age-Group Administration The product is generally not recommended for infants under 1 year of age (Syrup), children under 6 years (Drops), or children under 12 years (Tablets). Dosing volumes are tiered specifically for children (e.g., 1–5 years, 6–11 years) and adolescents/adults (12+ years).
Missed-Dose Rules Instructions state that users must not take a double dose to compensate for a forgotten scheduled dose, but should continue with the next dose at the regular time.

Connection to the Overall Use Protocol

The protocol mandates a short-term, structured course of oral therapy administered three times daily, with the exact dose being highly dependent on the chosen formulation and the patient’s age. This usage is further structured by specific administrative rules, such as taking tablets before meals and liquid forms with a calibrated measure. The protocol defines a maximum short-term duration, typically requiring medical consultation if improvement is not observed within 7 days to two weeks.

Recent Clinical Evidence

Research evidence / Overview of Studies for Bronchipret

This overview summarizes the available research into the fixed combination of herbal extracts in Bronchipret, focusing only on the type of studies conducted, what they measured, and what remains unclear, without offering clinical advice or guarantees.


Evidence for Use in Acute Bronchitis with Productive Cough

Research investigating the use of the thyme and ivy/primrose combination for acute disruptive episodes primarily consists of short-term Randomized Controlled Trials (RCTs) and controlled multi-centre studies. These controlled studies were used to explore how symptoms change over time in adult patients with acute bronchitis who were experiencing a cough that produces mucus.

The studies monitored patient experience using the Bronchitis Severity Score (BSS), a multi-item scale used to measure changes in cough severity and related discomfort. Findings from these trials and subsequent systematic reviews report that patterns observed in the studies included changes in the BSS score and measurements of the frequency of coughing fits during the observed period.


Comparing Bronchipret to Other Therapies or Placebo

A necessary step in evaluating any medicine is researching how it compares to an inactive substance (placebo) or another specific treatment examined in the study. For the thyme/ivy and thyme/primrose combinations, researchers have conducted trials comparing them to both inactive substances and to specific single-extract preparations. While research describes the measured difference in symptom patterns between the active combination and placebo groups over the short term, some comparative evidence is lacking or shows varying results.


What Research Gaps and Uncertainties Remain

The research landscape contains multiple controlled trials, but the long-term patterns are not fully established because evidence for outcomes extending beyond the immediate short-term treatment period is very limited. The prevalence of non-randomized or open-label study designs in the overall evidence pool can make findings less certain than those from fully blinded RCTs. Furthermore, high-quality RCT data for children and adolescents remain insufficient or come from smaller studies, and data for certain groups remain insufficient, particularly for patients with complex medical histories.

Key Studies & References

  1. A comparison of the efficacy and safety of a fixed combination of thyme and ivy leaves extract versus single-extract preparation in patients with acute cough

Frequently Asked Questions (FAQ)

Common questions about Bronchipret (FAQ)

Q: What kind of cough is Bronchipret best used for?

A: According to official product information, Bronchipret is primarily used to relieve symptoms associated with acute inflammation of the airways. This typically involves coughs that are associated with the production of excessive or thick mucus, known as a productive cough.

Q: Does Bronchipret help with dry cough or chesty cough?

A: Bronchipret is specifically formulated to help with a chesty or productive cough because its mechanism aims to thin the mucus and increase its expulsion from the respiratory tract. It acts as an expectorant, which helps clear the airways, rather than suppressing the cough reflex itself.

Q: Is Bronchipret an expectorant or a cough suppressant?

A: Bronchipret is classified in regulatory documents as an expectorant (aids mucus expulsion) and a spasmolytic (relaxes muscle tissue) in the airways. Its primary function is to help loosen and expel mucus from the lungs, not to stop the cough entirely.

Q: Is Bronchipret suitable for children?

A: The suitability of Bronchipret for children depends on their age and the specific formulation being used. Official documentation indicates the Syrup is approved for children from 1 year of age. Drops are generally for children from 6 years, and the Tablets from 12 years.

Q: What is the difference between Bronchipret and simple thyme syrup?

A: Bronchipret is a fixed combination of plant extracts, usually Thyme and either Ivy or Primrose. Simple thyme syrup contains only a single active ingredient. The combination formulation is designed to provide multiple therapeutic actions, due to the combined effects of its components on the airways.

Q: Are there different forms of Bronchipret, like drops or tablets?

A: Yes, Bronchipret is generally available in several official formulations. These typically include a Syrup, an oral Drops solution, and Film-Coated Tablets, depending on regional availability and specific product lines.

Q: Do any common cold medicines interact with Bronchipret?

A: Official regulatory documentation indicates that no known interactions with other simultaneously administered medicinal products, including common cold medicines, have been reported or documented to date. It is important to inform a healthcare professional about all medicines being taken.

Q: Is it safe to take Bronchipret with pain relievers like paracetamol?

A: Regulatory documents state that no known interactions with other medicines, including over-the-counter pain relievers, have been reported or documented. Nonetheless, comprehensive interaction studies covering all combinations are not available.

Q: Does Bronchipret have any long-term side effects?

A: The adverse reactions listed in the official regulatory documents (such as gastrointestinal issues or hypersensitivity) are generally short-term. The research overview indicates that long-term safety data extending beyond the immediate treatment period are limited or not fully established.

Q: What are the inactive ingredients in Bronchipret?

A: The inactive ingredients (excipients) vary depending on the specific formulation. These ingredients may include specific sugars, such as maltitol or lactose. If a user has known intolerances to any sugars, consultation with a healthcare professional is advised before use.

Q: Can Bronchipret be taken with food, or is it better on an empty stomach?

A: The timing depends on the formulation: Film-Coated Tablets should be swallowed before meals. Liquid forms (Syrup/Drops) can be taken independent of meals, although taking them after meals is often suggested for individuals with a sensitive stomach.

Q: Is it normal to see small bits of sediment in the liquid Bronchipret?

A: Yes, according to the official storage information, liquid forms of the medicine may experience some natural turbidity or sediment formation when stored for a long time. This change in appearance is generally not reported to impair the effectiveness of the medicine.

Q: Does Bronchipret make you drowsy or sleepy?

A: Drowsiness or sleepiness is not listed among the common, uncommon, or very rare adverse reactions in the official regulatory documentation for Bronchipret.

Q: Can Bronchipret interact with herbal teas or supplements?

A: Official documentation reports no known interactions with other medicines. However, comprehensive studies specifically on the interaction with all herbal teas or supplements have not been conducted. Patients should inform their doctor or pharmacist about all herbal products they use.

Q: What age group is Bronchipret typically recommended for?

A: Bronchipret is generally recommended for the short-term treatment of acute cough symptoms in children aged 1 year and above (depending on the formulation) and adolescents/adults, following the specific age restrictions for each product type.

Q: Can Bronchipret interact with medications for acid reflux?

A: Official regulatory documents report no known interactions with other medicines. However, individuals with a history of gastritis or peptic ulcers are advised to use the medicine with caution, as it contains herbal extracts that may affect the gastric lining.

Q: Can Bronchipret be used alongside antibiotics?

A: Regulatory documents state that no known interactions with other simultaneously administered medicines, including prescription drugs like antibiotics, have been reported. Consultation with a healthcare professional is recommended when co-administering any product.

Q: Do different Bronchipret products have different concentrations of active ingredients?

A: Yes, official regulatory information confirms that different formulations, such as the Syrup and the Drops, contain the active herbal extracts in varying concentrations per unit of volume or dosage to meet the needs of different age groups and administration forms.

Q: How long after opening should I dispose of the syrup/drops?

A: To ensure product quality and stability, the Syrup and Drops formulations should be used within 6 months after the initial opening. Disposal is required if this period is exceeded.

Q: Can people with diabetes use Bronchipret?

A: Since the medicine may contain sugars or sugar substitutes, such as maltitol or lactose, as excipients, consultation with a healthcare professional is necessary for individuals with diabetes or known sugar intolerances.

Q: Are there any food restrictions while taking Bronchipret?

A: Regulatory documents indicate no specific known interactions with food or drink. The main requirements relate to the timing of administration relative to meals (e.g., taking tablets before meals), but there are no mandated food restrictions.

Q: What is the typical duration of treatment with Bronchipret?

A: The medicine is intended for a short-term, structured course of therapy for acute symptoms. If a user does not observe an improvement in symptoms within 7 days to two weeks, medical consultation is advised if symptoms persist beyond this period.

Q: What is the difference in action between thyme and ivy in Bronchipret?

A: The Ivy leaf components are noted for modulating the beta2-Adrenergic Receptor to help relax smooth muscle, contributing to spasmolytic effects. The Thyme components primarily inhibit the PDE4 enzyme. Both extracts contribute to the overall effect of thinning mucus and aiding in secretion expulsion.

Q: Why is ivy leaf extract included in the Bronchipret formula?

A: Ivy leaf extract is included because it has a history of use recognized by the EMA as a traditional herbal medicine used as an expectorant (aids the expulsion of phlegm). Mechanistically, it helps by modulating receptors in the airways, contributing to a muscle-relaxing, or spasmolytic, effect.

How should Bronchipret be stored and disposed of?

How to Store and Dispose of Bronchipret

Storage of Bronchipret must adhere strictly to official regulatory requirements to ensure product stability.

Storage Requirements

Formulation Temperature Requirement Additional Storage Rule
Syrup TE / TP Tablets Do not store above 25°C
Syrup TE Do not store above 25°C Store in original container; protect from light
Drops No special temperature conditions required

Both the Syrup TE and Drops formulations must be used within 6 months after the initial opening. A mandatory requirement for all forms is to keep the medicine out of the sight and reach of children.

Disposal

Unused or expired Bronchipret must not be disposed of by flushing it down the toilet or pouring it down a sink. Disposal must follow local regulatory requirements, often by utilizing a community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronchipret found in:

A-Z Index: